Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 17/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 16/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 9/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177580 | 0.87 | PIK3CD (0.77) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL303269 | 0.85 | HTT (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL304345 | 0.78 | PIK3CA (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL1851087 | 0.77 | PIK3CD (0.63) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL1860536 | 0.76 | PIK3CD (0.60) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL1853490 | 0.75 | HTT (0.64) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL1177740 | 0.74 | HTT (0.74) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL1853780 | 0.74 | PIK3CD (0.64) | PIK3CDPIK3CBPIK3CGPIK3CAHTT | |
| SCHEMBL9289708 | 0.74 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CGPIK3CATSHR | |
| SCHEMBL944578 | 0.73 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CGPIK3CAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PIK3CD 15/4885PIK3CB 17/4885PIK3CG 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.